These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19761363)

  • 1. Conference Scene: Pharmacogenomics at the second PharmSciFair 2009: adverse drug reactions and clinical implementation.
    van Schie RM; Cascorbi I; Maitland-van der Zee AH
    Pharmacogenomics; 2009 Sep; 10(9):1389-91. PubMed ID: 19761363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conference scene: initiatives on future biobanking in pharmacogenomics.
    Vijverberg S; Daly AK; Maitland-van der Zee AH
    Pharmacogenomics; 2009 Jul; 10(7):1135-8. PubMed ID: 19604088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From personalized medicine to personalized justice: the promises of translational pharmacogenomics in the justice system.
    Wong SH; Happy C; Blinka D; Gock S; Jentzen JM; Donald Hon J; Coleman H; Jortani SA; Lucire Y; Morris-Kukoski CL; Neuman MG; Orsulak PJ; Sander T; Wagner MA; Wynn JR; Wu AH; Yeo KT
    Pharmacogenomics; 2010 Jun; 11(6):731-7. PubMed ID: 20504247
    [No Abstract]   [Full Text] [Related]  

  • 4. Conference scene: pharmacogenomics: from cell to clinic (part 2).
    Siest G; Medeiros R; Melichar B; Stathopoulou M; Van Schaik RH; Cacabelos R; Abt PM; Monteiro C; Gurwitz D; Queiroz J; Mota-Filipe H; Ndiaye NC; Visvikis-Siest S
    Pharmacogenomics; 2014 Apr; 15(6):739-44. PubMed ID: 24897282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics: historical perspective and current status.
    Charlab R; Zhang L
    Methods Mol Biol; 2013; 1015():3-22. PubMed ID: 23824846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics: from cell to clinic (Part 1).
    Siest G; Medeiros R; Melichar B; Stathopoulou M; Van Schaik RH; Cacabelos R; Abt PM; Monteiro C; Gurwitz D; Queiroz J; Mota-Filipe H; Ndiaye NC; Visvikis-Siest S
    Pharmacogenomics; 2014 Apr; 15(5):593-9. PubMed ID: 24798716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug therapy and pharmacogenomics--hopes and facts].
    Müller-Zellenberg U; Müller M
    Wien Med Wochenschr; 2005 Feb; 155(3-4):45-9. PubMed ID: 15791775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics at the tipping point: challenges and opportunities.
    Roden DM; Tyndale RF
    Clin Pharmacol Ther; 2011 Mar; 89(3):323-7. PubMed ID: 21326256
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacogenetics: development issues and solutions for safe and effective medicines.
    Arnold HP; McHale D
    Pharmacogenomics; 2006 Mar; 7(2):149-55. PubMed ID: 16515393
    [No Abstract]   [Full Text] [Related]  

  • 10. Emergence and evolution of pharmacogenetics and pharmacogenomics in clinical pharmacy over the past 40 years.
    Streetman DS
    Ann Pharmacother; 2007 Dec; 41(12):2038-41. PubMed ID: 17956958
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice.
    Manolopoulos VG
    Clin Chem Lab Med; 2007; 45(7):801-14. PubMed ID: 17617019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenomics and public health: implementing 'populationalized' medicine.
    Mette L; Mitropoulos K; Vozikis A; Patrinos GP
    Pharmacogenomics; 2012 May; 13(7):803-13. PubMed ID: 22594512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics: What the Doctor Ordered?
    Eissenberg JC; Aurora R
    Mo Med; 2019; 116(3):217-225. PubMed ID: 31527945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The promises of personalized medicine.
    Cascorbi I
    Eur J Clin Pharmacol; 2010 Aug; 66(8):749-54. PubMed ID: 20563567
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade.
    Alessandrini M; Chaudhry M; Dodgen TM; Pepper MS
    OMICS; 2016 Oct; 20(10):593-603. PubMed ID: 27643672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics in dermatology: tools for understanding gene-drug associations.
    Daneshjou R; Huddart R; Klein TE; Altman RB
    Semin Cutan Med Surg; 2019 Mar; 38(1):E19-E24. PubMed ID: 31051019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.
    O'Donnell PH; Bush A; Spitz J; Danahey K; Saner D; Das S; Cox NJ; Ratain MJ
    Clin Pharmacol Ther; 2012 Oct; 92(4):446-9. PubMed ID: 22929923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics: bridging the gap between science and practice.
    Lee KC; Ma JD; Kuo GM
    J Am Pharm Assoc (2003); 2010; 50(1):e1-14; quiz e15-7. PubMed ID: 20368146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of pharmacogenomics for drug development and clinical practice.
    Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA
    Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conference Scene: Lessons learned from the 5th Statistical Analysis Workshop of the Pharmacogenetics Research Network.
    Atkinson EJ; McDonnell SK; Witte JS; Crawford DC; Fan Y; Fridley B; Li D; Li L; Rodin A; Sadee W; Speed T; Weiss ST; Yang J; Yerges L; Schaid DJ
    Pharmacogenomics; 2010 Mar; 11(3):297-303. PubMed ID: 20235785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.